S
Safi Bahcall
CEO, Synta Pharmaceuticals
FORMER PROFESSION: Astrophysicist (like both his parents)
GOAL: For Synta to be the next Celgene or Genentech
Until 2003, everything was abstract. Papers, ideas, concepts, and theories. And then I went to Boston to meet the first patient who was getting dosed with our first drug for the first time. The patient was a young guy, with an IV bag going into his arm, who had cancer. It was our drug in that bag, and he was looking at me, hoping that our drug would make him not die. The doctor and nurse just left, so I sat down in the chair next to his bed, and we started talking—about travelling, restaurants, biking. And all the stuff that I've done—the stock options, business plans, whatever—they all just melted way. Everything in the past just faded. And I realized that everything that counted, it was there. It's those moments that reframe everything and let you realize how important it is to do what we are doing."
Safi Bahcall
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.